MGMT and glioblastoma: Multivariate analysis including these variables confirmed that age (HR=2.298, 95% CI: 1.031-5.122, P=0.042), methylation of the MGMT promoter (HR=0.343, 95% CI: 0.188-0.628, P=0.001), and the expression level of DIAPH3 (HR=0.487, 95% CI: 0.289-0.819, P=0.007) can independently predict the OS of glioblastoma patients (Figure 2F).